Novartis AG's dividends per share for the
three
months ended in Mar. 2024 was CHF0.00. Its dividends per share for the trailing twelve months (TTM) ended in Mar. 2024 was CHF0.00. Its Dividend Payout Ratio for the
three
months ended in Mar. 2024 was 0.00. As of today, Novartis AG's Dividend Yield % is 0.00%.
Warning Sign:
If a company's dividend payout ratio is too high, its dividend may not be sustainable. The dividend payout ratio of Novartis AG is 0.85, which seems too high.
During the past 12 months, Novartis AG's average Dividends Per Share Growth Rate was 2.90% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 3.80% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 1.70% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 2.30% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Novartis AG was 18.50% per year. The lowest was 0.20% per year. And the median was 5.75% per year.
For more information regarding to dividend, please check our Dividend Page.
Novartis AG Dividends per Share Historical Data
The historical data trend for Novartis AG's Dividends per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Novartis AG's Dividends per Share
For the Drug Manufacturers - General subindustry, Novartis AG's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG's Dividend Yield % Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Novartis AG's Dividend Yield % falls into.
Novartis AG Dividends per Share Calculation
Dividends paid to per common share.
Novartis AG (XSWX:NOVNEE) Dividends per Share Explanation
1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.
Novartis AG's Dividend Payout Ratio for the quarter that ended in Mar. 2024 is calculated as
During the past 13 years, the highest Dividend Payout Ratio of Novartis AG was 1.19. The lowest was 0.33. And the median was 0.85.
Warning Sign:
If a company's dividend payout ratio is too high, its dividend may not be sustainable. The dividend payout ratio of Novartis AG is 0.85, which seems too high.
2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.
During the past 13 years, the highest Dividend Yield of Novartis AG was 4.63%. The lowest was 2.91%. And the median was 3.89%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novartis AG Dividends per Share Related Terms
Thank you for viewing the detailed overview of Novartis AG's Dividends per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XSWX:NOVNEE has been successfully added to your 